BMY vs GSK: Which Biopharma Giant Has Better Prospects for Now?

Key Takeaways BMY's growth portfolio, led by Opdivo and Reblozyl, is partially offsetting legacy drug declines.GSK is driving growth with strong HIV, oncology and respiratory launches, though vaccine sales face pressure.GSK shares outperformed BMY over the past year, while BMY offers a higher dividend but carries heavy debt.Bristol Myers Squibb (BMY) and GSK PLC (GSK) are among the largest global biopharma companies with broad and diverse portfolios.Bristol Myers Squibb focuses on the discovery, development ...